Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lete-cel with or without Pembrolizumab in Advanced NSCLC
NCT03709706Phase 2Terminated
- Sponsor
- GSK
- Start
- Dec 2018
- Primary completion
- Jun 2022
- Modality
- CAR-T Cells
- Countries
- 5
01
Overview
A Phase 2 trial of letetresgene autoleucel in non-small cell lung cancer (NSCLC), sponsored by GSK. Started Dec 2018; status: terminated.
02
Drugs
letetresgene autoleucel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03709706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03709706.